AIDGenomics
AIDGenomics21About
What does AIDGenomics do?
AID Genomics enables mass adoption of precision medicine by providing physicians with state-of-the-art genomic diagnostics. They leverage next-generation sequencing, miRNA, epigenetics, and AI-based analytics to deliver affordable, individualized diagnostics for better treatment choices and improved patient care. Their focus includes redefining cancer care through early detection and personalized genomic insights.
What is AIDGenomics's revenue?
StartupHub estimates AIDGenomics's annual revenue at $7.8M (range $4.7M to $17.7M, 67% confidence), based on comparable companies in the sector.
When was AIDGenomics founded?
AIDGenomics was founded in 2014.
What industry does AIDGenomics operate in?
AIDGenomics operates in Healthcare, Personalized, Next Generation Sequencing, HealthTech, MedTech, Genomics.
How many employees does AIDGenomics have?
AIDGenomics has approximately 46 people on record.
Lymesignal is an AI-assisted platform that transforms publicly available Lyme disease discussions into organized, searchable community knowledge.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
A science-based digital program and app designed to help adults manage ADHD symptoms and build coping skills.
AI-powered platform for personalized weight management and health coaching.
Recordatorios por WhatsApp para el paciente y tranquilidad para quien lo acompaña. Gratis, sin apps que descargar.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 10 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.